This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Labcorp (LH) Extends MRD Clinical Research With New Launch
by Zacks Equity Research
Labcorp (LH) Plasma Detect MRD solution advances its leadership in precision oncology across the solid tumor oncology care continuum.
Here's Why Investors Should Retain Labcorp (LH) Stock for Now
by Zacks Equity Research
Investors are optimistic about Labcorp (LH) on the continued strength of Central Labs, which is driving the success of the biopharma segment.
OPKO Health (OPK) to Restructure After Asset Buyout by Labcorp
by Zacks Equity Research
OPKO Health (OPK) expects to re-establish profitability in its clinical laboratory business via its latest efforts to streamline its laboratory services business.
Labcorp (LH) to Boost Clinical Diagnostics With New Deal
by Zacks Equity Research
The recent deal will augment Labcorp's (LH) laboratory services network and expand access to the company's high-quality clinical laboratory services.
Labcorp (LH) Boost Diagnostics Suite With New Biomarker Test
by Zacks Equity Research
Labcorp's (LH) pTau217 test is a pivotal blood biomarker intended to aid in the diagnosis of Alzheimer's disease.
Labcorp (LH) Presents New Research on Precision Diagnostics
by Zacks Equity Research
Labcorp's (LH) new research shows how biomarker testing can help close testing gaps and guide tailored therapy for patients with epithelial ovarian cancer.
Labcorp (LH) Expands Strategic Alliances, Test Sales Fall
by Zacks Equity Research
Labcorp (LH) continues to progress in terms of integrating hospital partnerships and acquisitions.
LH or COO: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
LH vs. COO: Which Stock Is the Better Value Option?
Are Investors Undervaluing Labcorp (LH) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Labcorp (LH) Introduces Weight Loss Management Portfolio
by Zacks Equity Research
Labcorp's (LH) Weight Loss Management service includes proven tests from its extensive menu and simplifies the procedure for both physicians and patients.
Here's Why Investors Should Hold Labcorp (LH) Stock for Now
by Zacks Equity Research
Targeted development in high-growth areas and strategic partnerships bode well for Labcorp (LH).
Is Labcorp (LH) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Labcorp (LH) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Labcorp (LH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
LH vs. COO: Which Stock Is the Better Value Option?
by Zacks Equity Research
LH vs. COO: Which Stock Is the Better Value Option?
Compared to Estimates, Labcorp (LH) Q4 Earnings: A Look at Key Metrics (Revised)
by Zacks Equity Research
Although the revenue and EPS for Labcorp (LH) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Labcorp (LH) Surpasses Q4 Earnings and Revenue Estimates (Revised)
by Zacks Equity Research
Labcorp (LH) delivered earnings and revenue surprises of 0.30% and 0.86%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Labcorp (LH) Q4 Earnings and Revenues Beat, Margins Fall
by Zacks Equity Research
Strength in Diagnostics Laboratories and Biopharma Laboratory Services businesses contributes to Labcorp's (LH) Q4 performance.
Compared to Estimates, Labcorp (LH) Q4 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for Labcorp (LH) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Labcorp (LH) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Labcorp (LH) delivered earnings and revenue surprises of 0.30% and 0.86%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Labcorp (LH) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
by Zacks Equity Research
Get a deeper insight into the potential performance of Labcorp (LH) for the quarter ended December 2023 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Analysts Estimate Labcorp (LH) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Labcorp (LH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Labcorp (LH) to Report Q4 Earnings: What's in the Cards? (Revised)
by Zacks Equity Research
Labcorp's (LH) fourth-quarter 2023 performance is likely to have demonstrated strength across its core businesses.
Labcorp (LH) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Labcorp's (LH) fourth-quarter 2023 performance is likely to have demonstrated strength across its core businesses.
LabCorp (LH) Unveils Test for Preeclampsia in Pregnant Women
by Zacks Equity Research
LabCorp (LH) test System, which is available through clinicians, is the first FDA-cleared biomarker test to aid in the risk assessment of progression to severe preeclampsia.
Quest Diagnostics (DGX) Advances in Cancer Research With New Deal
by Zacks Equity Research
Quest Diagnostics' (DGX) subsidiary Haystack Oncology collaborates with TriSalus Life Sciences to improve therapeutic options for aggressive forms of cancer.